This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

President Donald Trump’s budget office has rescinded an order freezing spending on federal grants, less than two days after ...

Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...